Information de reference pour ce titreAccession Number: | 00007890-201806000-00027.
|
Author: | Abbott, Kevin C. MD, MPH 1; Fwu, Chyng-Wen DrPH 2; Eggers, Paul W. PhD 1; Eggers, Anne W. RPH 3; Kline, Prudence P. MD 4; Kimmel, Paul L. MD 1
|
Institution: | (1) Division of Kidney, Urologic and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD. (2) Social & Scientific Systems, Inc., Silver Spring, MD. (3) Independent Consultant, Olney, MD. (4) Department of Medicine, George Washington University, Washington, DC.
|
Title: | |
Source: | Transplantation. 102(6):994-1004, June 2018.
|
Abstract: | Background: Centers for Disease Control and Prevention guidelines recommend caution in prescribing opioids for chronic pain. The characteristics of opioid prescription (OpRx) among kidney transplant (KTx) recipients have not been described in a national population.
Methods: We assessed OpRx prevalence among prevalent KTx recipients, and associated duration (long-term, defined as >=90 days in a year) and dosing (in morphine milligram equivalents per day of <50, 50-89, and >=90) with outcomes, death and graft loss, among incident KTx recipients using 2006-2010 US Renal Data System files, including Medicare Part D for medication ascertainment. Cox models controlled for recipient factors.
Results: Of 36,486 KTx recipients in the 2010 prevalent cohort, approximately 14.6% had long-term OpRx. The strongest association with long-term OpRx after KTx was long-term OpRx before KTx (64%; adjusted odds ratio, 95% confidence interval, 95.2, 74.2-122.1). Incident KTx recipients with long-term OpRx had increased risk of mortality and graft loss compared with those without OpRx or short-term OpRx after KTx. This risk was highest among recipients with long-term OpRx doses of >=90 morphine milligram equivalents or higher per day (adjusted hazard ratio, 95% confidence interval, 1.61, 1.24-2.10 for death, and 1.33, 1.05-1.67 for graft loss, respectively).
Conclusions: In contrast to either no or short-term OpRx, long-term, and especially long-term high-dose OpRx, is associated with increased risk of death and graft loss in US KTx recipients. Causal relationships cannot be inferred, and OpRx may be an illness marker. Nevertheless, efforts to treat pain effectively in KTx recipients with less toxic interventions and decrease OpRx deserve consideration.
Copyright (C) 2018 Wolters Kluwer Health, Inc. All rights reserved.
|
References: | 1. Lentine KL, Lam NN, Schnitzler MA, et al. Predonation prescription opioid use: a novel risk factor for readmission after living kidney donation. Am J Transplant. 2017;17:744-753.
2. Randall HB, Alhamad T, Schnitzler MA, et al. Survival implications of opioid use before and after liver transplantation. Liver Transpl. 2017;23:305-314.
3. Lentine KL, Lam NN, Xiao H, et al. Associations of pre-transplant prescription narcotic use with clinical complications after kidney transplantation. Am J Nephrol. 2015;41:165-176.
4. Lentine KL, Yuan H, Tuttle-Newhall JE, et al. Quantifying prognostic impact of prescription opioid use before kidney transplantation through linked registry and pharmaceutical claims data. Transplantation. 2015;99:187-196.
5. Kuo YF, Raji MA, Chen NW, et al. Trends in opioid prescriptions among part D Medicare recipients from 2007 to 2012. Am J Med. 2016;129:221.e21-221.230.
6. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10:113-130.
7. Kimmel PL, Fwu CW, Abbott KC, et al. Opioid prescription, morbidity, and mortality in United States dialysis patients. J Am Soc Nephrol. 2017;28:3658-3670.
8. Kulshrestha S, Barrantes F, Samaniego M, et al. Chronic opioid analgesic usage post-kidney transplantation and clinical outcomes. Clin Transplant. 2014;28:1041-1046.
9. Von Korff M, Saunders K, Thomas Ray G, et al. De facto long-term opioid therapy for noncancer pain. Clin J Pain. 2008;24:521-527.
10. CMS. Opioid Morphine Equivalent Conversion Factors. Available at: www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/Downloads/Opioid-Morphine-EQ-Conversion-Factors-March-2015.pdf. Accessed December 13, 2016.
11. Kimmel PL, Fwu CW, Abbott KC, et al. Racial disparities in poverty account for mortality differences in US Medicare beneficiaries. SSM Popul Health. 2016;2:123-129.
12. Kimmel PL, Fwu CW, Eggers PW. Segregation, income disparities, and survival in hemodialysis patients. J Am Soc Nephrol. 2013;24:293-301.
13. Garg JP, Chasan-Taber S, Blair A, et al. Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial. Arthritis Rheum. 2005;52:290-295.
14. Ingram DD, Franco SJ. NCHS urban-rural classification scheme for counties. Vital Health Stat 2. 2012;154:1-65.
15. United States Census Bureau. Median Household Income in the Past 12 months: 2007-2011 American Community Survey 5-year Estimates. Available at: https://factfinder.census.gov/fa...- ouverture dans une nouvelle fenêtre. Accessed September 20, 2017.
16. CDC Guideline for Prescribing Opioids for Chronic Pain. Available at: www.cdc.gov/drugoverdose/pdf/guidelines_at-a-glance-a.pdf. Accessed September 28, 2017.
17. Deyo RA, Hallvik SE, Hildebran C, et al. Association between initial opioid prescribing patterns and subsequent long-term use among opioid-naive patients: a statewide retrospective cohort study. J Gen Intern Med. 2017;32:21-27.
18. Barnett ML, Olenski AR, Jena AB. Opioid-prescribing patterns of emergency physicians and risk of long-term use. N Engl J Med. 2017;376:663-673.
19. CDC. Opioid prescribing: where you live matters. Available at: www.cdc.gov/vitalsigns/pdf/2017-07-vitalsigns.pdf. Accessed September 28, 2017.
20. Masajtis-Zagajewska A, Pietrasik P, Krawczyk J, et al. Similar prevalence but different characteristics of pain in kidney transplant recipients and chronic hemodialysis patients. Clin Transplant. 2011;25:E144-E151.
21. Breitenstein A, Stumpe KD, Gnannt R, et al. Calcineurin inhibitor-induced pain syndrome after kidney transplantation-a rare but disabling condition. NDT Plus. 2011;4:63-66.
22. Prommer E. Calcineurin-inhibitor pain syndrome. Clin J Pain. 2012;28:556-559.
23. Abbott KC, Oglesby RJ, Agodoa LY. Hospitalized avascular necrosis after renal transplantation in the United States. Kidney Int. 2002;62:2250-2256.
24. Abbott KC, Koff J, Bohen EM, et al. Maintenance immunosuppression use and the associated risk of avascular necrosis after kidney transplantation in the United States. Transplantation. 2005;79:330-336.
25. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain-United States, 2016. MMWR Recomm Rep. 2016;65:1-49.
26. Cheatle MD. Biopsychosocial approach to assessing and managing patients with chronic pain. Med Clin North Am. 2016;100:43-53.
27. Garland EL. Treating chronic pain: the need for non-opioid options. Expert Rev Clin Pharmacol. 2014;7:545-550.
28. Veilleux JC, Colvin PJ, Anderson J, et al. A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction. Clin Psychol Rev. 2010;30:155-166.
29. Castro MM, Daltro C, Kraychete DC, et al. The cognitive behavioral therapy causes an improvement in quality of life in patients with chronic musculoskeletal pain. Arq Neuropsiquiatr. 2012;70:864-868.
30. Pigeon WR, Moynihan J, Matteson-Rusby S, et al. Comparative effectiveness of CBT interventions for co-morbid chronic pain and insomnia: a pilot study. Behav Res Ther. 2012;50:685-689.
31. Cukor D, Ver Halen N, Asher DR, et al. Psychosocial intervention improves depression, quality of life, and fluid adherence in hemodialysis. J Am Soc Nephrol. 2014;25:196-206.
32. Kimmel PL. The weather and quality of life in ESRD patients: everybody talks about it, but does anybody do anything about it? Semin Dial. 2013;26:260-262.
33. Davison SN, Jhangri GS. The impact of chronic pain on depression, sleep, and the desire to withdraw from dialysis in hemodialysis patients. J Pain Symptom Manage. 2005;30:465-473.
34. Davison SN. Chronic kidney disease: psychosocial impact of chronic pain. Geriatrics. 2007;62:17-23.
35. Weiss RD, Potter JS, Griffin ML, et al. Long-term outcomes from the national drug abuse treatment clinical trials network prescription opioid addiction treatment study. Drug Alcohol Depend. 2015;150:112-119.
36. Lee JD, Friedmann PD, Kinlock TW, et al. Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. N Engl J Med. 2016;374:1232-1242.
37. Volkow ND, Collins FS. The role of science in addressing the opioid crisis. N Engl J Med. 2017;377:391-394.
38. Harris TJ, Nazir R, Khetpal P, et al. Pain, sleep disturbance and survival in hemodialysis patients. Nephrol Dial Transplant. 2012;27:758-765.
|
Language: | English.
|
Document Type: | Original Clinical Science-General.
|
Journal Subset: | Clinical Medicine. Life & Biomedical Sciences.
|
ISSN: | 0041-1337
|
NLM Journal Code: | wej, 0132144
|
DOI Number: | https://dx.doi.org/10.1097/TP.00...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|